OncoSynergy is a biotechnology company focused on immuno-oncology. It develops drug candidates with resistance mechanism inhibitors (RMIs). The company provides a lead candidate intended for the treatment of glioblastoma (aggressive brain cancer) and ovarian cancer. The drug is also in development as an Ebola virus entry inhibitor.